MyMyelomaTeam

Kyprolis (Carfilzomib) is a medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried other therapies. It is often combined with a corticosteroid and other drugs such as Revlimid in specific chemotherapy regimens. Kyprolis is administered as an intravenous infusion Show Full Answer

Kyprolis (Carfilzomib) is a medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried other therapies. It is often combined with a corticosteroid and other drugs such as Revlimid in specific chemotherapy regimens. Kyprolis is administered as an intravenous infusion and is a member of a class of drugs called proteasome inhibitors, which work by interfering with cell division.

Common side effects include:
- Anemia
- Fatigue
- Fever
- Nausea
- Diarrhea
- Cough
- Cold or flu symptoms
- Trouble breathing
- Swelling in the extremities

Rare but serious side effects include:
- Heart failure
- Kidney failure
- Tumor lysis syndrome
- Lung toxicity
- Hypertension
- Bleeding in the lungs, brain, or gastrointestinal system
- Fetal harm in pregnant women

For more details, you can visit the Kyprolis page on MyMyelomaTeam: [Kyprolis (Carfilzomib) for Myeloma](https://www.mymyelomateam.com/treatments/kyprolis).

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Kyprolis (Carfilzomib) for Myeloma | MyMyelomaTeam

Carvykti (Ciltacabtagene autoleucel) for Myeloma | MyMyelomaTeam